Brief: SanBio and Teijin to terminate licensing agreement regarding SB623 for stroke treatment
14/02/2018 09:13
Feb 14 (Reuters) - SanBio Co Ltd 4592.T
* Says co and Teijin Limited would terminate the exclusive
licensing agreement signed in 2009, regarding the development
and marketing of SB623 for stroke treatment in Japan
Source text in Japanese: https://goo.gl/1xt25t
Further company coverage: 4592.T
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 010 62674724;
Reuters Messaging: Tingting.liu@thomsonreuters.com@reuters.net))